Physician profile
John M Mccune
NPI 1750347225
$554.25
in general payments reported to CMS, 2019-2025
13 companies · $31.93 in 2025
The $31.93 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108 · 2020: $54.68 · 2021: $41.92 · 2022: $124 · 2023: $157 · 2024: $36.08 · 2025: $31.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $224.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $98.62 | 2020-2022 | |
| Smith+Nephew, INC. | $88.78 | 2023-2025 | Collagenase Santyl, Oasis, Stravix |
| Organogenesis INC. | $80.44 | 2019 | |
| Next Science LLC | $44.85 | 2023 | Blastx, Xperience, Surgx |
| Bioventus LLC | $44.30 | 2022 | |
| Misonix INC | $43.98 | 2019-2021 | |
| Kci USA, INC. | $33.55 | 2022-2023 | V.A.C. Dermatac, Activ.A.C. |
| Polarityte, INC. | $28.37 | 2020 | |
| Kerecis Limited | $27.13 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Solventum Corporation | $18.97 | 2024 | Activ.A.C. |
| Mimedx Group, INC. | $17.11 | 2024 | |
| Sanara Medtech INC. | $14.29 | 2021 | |
| Reprise Biomedical, INC. | $13.86 | 2025 | Miro3d |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mccune listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.